Effects of Mobility Dose in Surgical Intensive Care Unit Patients

Status unconfirmed

Conditions studied: Sarcopenia, Muscle Weakness, Critical Illness

In brief

The primary aim of this study is to assess if the mobility dose that patients receive in the surgical intensive care unit (SICU) predicts adverse discharge disposition (primary endpoint), and muscle wasting diagnosed by bedside ultrasound (secondary endpoint).

Key facts

Study ID

NCT03196960

Run by

Massachusetts General Hospital

People needed

150

Starts

2017-05-22

Expected to finish

2018-12-01

Last updated by the study team

2018-09-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (18 years of age or greater)
• Barthel score ≥70 from a proxy describing patient function 2 weeks before admission
• Expected stay on the ICU of >=3 days

You may not qualify if…

• Patients transferred from other hospitals, long-term rehabilitation facilities or nursing homes with a preceding stay of more than 48 hours
• Hospitalization 1 month prior to ICU admission >7 days
• Discussion about changing the goals of care from cure to comfort
• High risk of persistent brain injury (GCS<5 motor component and presence of TBI)
• Patients with neurodegenerative diseases
• Subjects with absence of a lower extremity
• Patients with paraplegia or tetraplegia
• Pregnancy

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Klinikum Rechts der Isar — Munich, Bavaria, Germany (enrolling)
• Università degli Studi di Brescia — Brescia, Lombardy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.